Kaleido Bio discontinues Phase 2 KB109 study, ends collaboration with COPD Foundation

seekingalpha2022-01-31

In a 8-K filing, Kaleido Biosciences (NASDAQ:KLDO) announced that it has decided to halt work on a planned Phase 2 study of KB109 in patients with chronic obstructive pulmonary disease (COPD) study ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Xyl
2022-01-31
Xyl
[Smile]
CET 789
2022-01-31
CET 789
Great...
analyst
2022-01-31
analyst
Stonk la
Shandon
2022-01-31
Shandon
Ok
Deathflash
2022-01-31
Deathflash
Ok
TTrade
2022-01-31
TTrade
A like pls. Have a good day.

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2207385212?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-31 16:54","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2207385212","market":"us","top_or_hot":-1,"title":"Kaleido Bio discontinues Phase 2 KB109 study, ends collaboration with COPD Foundation","media":"seekingalpha","content":"<div>\n<p>In a 8-K filing, Kaleido Biosciences (NASDAQ:KLDO) announced that it has decided to halt work on a planned Phase 2 study of KB109 in patients with chronic obstructive pulmonary disease (COPD) study ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793349-kaleido-bio-discontinues-phase-2-kb109-study-ends-collaboration-with-copd-foundation\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kaleido Bio discontinues Phase 2 KB109 study, ends collaboration with COPD Foundation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKaleido Bio discontinues Phase 2 KB109 study, ends collaboration with COPD Foundation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-31 16:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793349-kaleido-bio-discontinues-phase-2-kb109-study-ends-collaboration-with-copd-foundation><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In a 8-K filing, Kaleido Biosciences (NASDAQ:KLDO) announced that it has decided to halt work on a planned Phase 2 study of KB109 in patients with chronic obstructive pulmonary disease (COPD) study ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793349-kaleido-bio-discontinues-phase-2-kb109-study-ends-collaboration-with-copd-foundation\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KLDO","symbol_name":"Kaleido Biosciences, Inc.","start_time":0,"source_url":"https://seekingalpha.com/news/3793349-kaleido-bio-discontinues-phase-2-kb109-study-ends-collaboration-with-copd-foundation","article_id":"2207385212","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2207385212","pubTimestamp":1643619254,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"In a 8-K filing, Kaleido Biosciences (NASDAQ:KLDO) announced that it has decided to halt work on a p","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"KLDO":"Kaleido Biosciences, Inc.","BK4166":"消费信贷","BK4007":"制药"},"translate_title":"凯莱多生物停止2期KB109研究，结束与COPD基金会的合作","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KLDO":1},"content_text":"In a 8-K filing, Kaleido Biosciences (NASDAQ:KLDO) announced that it has decided to halt work on a planned Phase 2 study of KB109 in patients with chronic obstructive pulmonary disease (COPD) study and terminate its agreement with the COPD Foundation. These decisions were made in order to re-align resources and focus the Company's efforts.After the company terminated development of KB109 and agreement with COPD Foundation, Piper Sandler analyst Edward Tenthoff lowered the firm's price target (PT) on KLDO to $4 from $19 and keeps an Overweight rating.Tenthoff's new $4 target is based on a projected enterprise value of $278M, down from $792M. He now values KB295 in ulcerative collitis at $228M and adds $50M for Kaleido's Microbiome Metabolic Therapies, or MMT, platform.Also, the analyst is removing $250M in value for KB109 for COPD, $153M for KB195 in urea cycle disorder and $181M for KB174 in hepatic encephalopathy.The revised T of $4, still implies a premium of ~130% to the last close of $1.74.Quant Rating on the stock is Strong Sell whereas Wall Street sell-siders have Buy Rating with average PT of $14.80.Earlier in August 2021, KLDO collaborated with COPD Foundation to study KB109.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9093210377,"gmtCreate":1643637122524,"gmtModify":1676533838366,"author":{"id":"3576812739314933","authorId":"3576812739314933","name":"Xyl","avatar":"https://static.tigerbbs.com/bc1d37faac006c24945fb274845dbd58","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093210377","repostId":2207385212,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093671854,"gmtCreate":1643624784164,"gmtModify":1676533837415,"author":{"id":"3574846237438181","authorId":"3574846237438181","name":"CET 789","avatar":"https://static.tigerbbs.com/b2cd0cadf666af297bd51826081757be","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":1},"htmlText":"Great...","listText":"Great...","text":"Great...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093671854","repostId":2207385212,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093649957,"gmtCreate":1643621622058,"gmtModify":1676533836946,"author":{"id":"3571041079572277","authorId":"3571041079572277","name":"analyst","avatar":"https://static.tigerbbs.com/a5642ab5babd7074a9aaa6a0286f63a8","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Stonk la","listText":"Stonk la","text":"Stonk la","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093649957","repostId":2207385212,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093656390,"gmtCreate":1643620400419,"gmtModify":1676533836764,"author":{"id":"3582031739174169","authorId":"3582031739174169","name":"Shandon","avatar":"https://static.tigerbbs.com/6f19607c2fa3f8fcda548608c98481a3","vip":1,"crmLevel":9,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093656390","repostId":2207385212,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093658885,"gmtCreate":1643620238331,"gmtModify":1676533836724,"author":{"id":"4102905095723380","authorId":"4102905095723380","name":"Deathflash","avatar":"https://static.tigerbbs.com/9641be057b54956245f679d3f78bb396","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093658885","repostId":2207385212,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093651530,"gmtCreate":1643620093686,"gmtModify":1676533836752,"author":{"id":"3586831371389056","authorId":"3586831371389056","name":"TTrade","avatar":"https://static.tigerbbs.com/7b6cfcc78c6b699734a72ed6f5035153","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"A like pls. Have a good day.&nbsp;","listText":"A like pls. Have a good day.&nbsp;","text":"A like pls. Have a good day.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093651530","repostId":2207385212,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":66,"commentSize":10,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2207385212"}